# GSK vs Regeneron Pharmaceuticals: stocks compared

URL: https://funkfolio.com/compare/gsk-vs-regn

> GSK ($98.7B, P/E 17.6) and Regeneron Pharmaceuticals ($99.1B, P/E 21.1) compared: size, valuation, margins, debt, cash and price change.

---

## GSK vs Regeneron Pharmaceuticals

GSK (GSK), health care, and Regeneron Pharmaceuticals (REGN), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

GSK and Regeneron Pharmaceuticals are valued at about the same: $98.7B and $99.1B. GSK trades at 17.6 times earnings and Regeneron Pharmaceuticals at 21.1; operating margins in their latest fiscal years were 24.3% and 24.9%. Over the past year GSK's share price has moved +6.42% and Regeneron Pharmaceuticals's +31.3%.

### Key facts

- **GSK market value:** $98.7B
- **Regeneron Pharmaceuticals market value:** $99.1B
- **GSK P/E:** 17.6
- **Regeneron Pharmaceuticals P/E:** 21.1
- **GSK revenue:** $43.4B FY to 2025-12-31
- **Regeneron Pharmaceuticals revenue:** $14.3B FY to 2025-12-31
- **Superinvestors holding both:** 2

Market values as of 18 Nov 2026, 05:03 UTC.

GSK vs Regeneron Pharmaceuticals: every measure side by side

| Measure | GSK | Regeneron Pharmaceuticals |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | United Kingdom | United States |
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size |  |  |
| Market cap | $98.7B lower | $99.1B higher |
| Revenue | $43.4B higher | $14.3B lower |
| Earnings | $7.6B higher | $4.5B lower |
| Employees | 66,841 higher | 15,410 lower |
| Total assets | $81.1B higher | $40.6B lower |
| Valuation |  |  |
| P/E | 17.6 lower | 21.1 higher |
| P/S | 2.3 lower | 6.9 higher |
| P/B | — | 2.9 |
| Dividend yield | — | 0.39% |
| Profitability |  |  |
| Operating margin | 24.3% lower | 24.9% higher |
| Balance sheet |  |  |
| Net assets | $21.7B lower | $31.3B higher |
| Total liabilities | $59.9B higher | $9.3B lower |
| Total debt | $19.2B higher | $2B lower |
| Cash on hand | $4.5B higher | $3.1B lower |
| Price change |  |  |
| Today | -2.32% lower | +0.56% higher |
| 1 year | +6.42% lower | +31.3% higher |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: GSK 103.6, Regeneron Pharmaceuticals 136.0.

- GSK (GSK)
- Regeneron Pharmaceuticals (REGN)

GSK and Regeneron Pharmaceuticals share prices over one year, rebased to 100: GSK ends at 103.6, Regeneron Pharmaceuticals at 136.0.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | GSK | REGN |
| --- | --- | --- |
| Nov 28, 2025 | 100.7 | 110.8 |
| Dec 31, 2025 | 103.2 | 109.6 |
| Jan 30, 2026 | 108.6 | 105.3 |
| Feb 27, 2026 | 124.4 | 111.0 |
| Mar 31, 2026 | 116.1 | 109.7 |
| Apr 30, 2026 | 110.1 | 100.4 |
| May 29, 2026 | 106.3 | 87.3 |
| Jun 30, 2026 | 110.3 | 88.5 |
| Jul 31, 2026 | 108.8 | 108.3 |
| Aug 31, 2026 | 105.7 | 113.5 |
| Sep 30, 2026 | 101.3 | 107.7 |
| Oct 30, 2026 | 104.2 | 131.7 |
| Nov 17, 2026 | 103.6 | 136.0 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (2)

- [Dodge & Cox team](https://funkfolio.com/gurus/dodge-and-cox) 1.1% / 1.9%
- [Jeremy Grantham (co-founder)](https://funkfolio.com/gurus/jeremy-grantham) 0.4% / 0.1%

#### GSK only (9)

- [Thomas Kahn](https://funkfolio.com/gurus/thomas-kahn) 0.9%
- [Primecap team](https://funkfolio.com/gurus/primecap) 0.8%
- [Charles Brandes (founder)](https://funkfolio.com/gurus/charles-brandes) 0.5%
- [Ken Fisher](https://funkfolio.com/gurus/ken-fisher) 0.5%
- [Tweedy, Browne team](https://funkfolio.com/gurus/tweedy-browne) 0.3%
- [Steve Cohen](https://funkfolio.com/gurus/steve-cohen) 0.2%
- [Howard Gleicher](https://funkfolio.com/gurus/howard-gleicher) 0.1%
- [Murray Stahl](https://funkfolio.com/gurus/murray-stahl) &lt;0.1%
- [Richard Pzena](https://funkfolio.com/gurus/richard-pzena) &lt;0.1%

#### Regeneron Pharmaceuticals only (8)

- [Mason Hawkins](https://funkfolio.com/gurus/mason-hawkins) 5.0%
- [Harry Burn](https://funkfolio.com/gurus/harry-burn) 3.0%
- [John Overdeck and David Siegel (founders)](https://funkfolio.com/gurus/two-sigma) 0.5%
- [Josef Lakonishok](https://funkfolio.com/gurus/josef-lakonishok) 0.3%
- [Jim Simons (1938–2024)](https://funkfolio.com/gurus/jim-simons) 0.3%
- [Cliff Asness](https://funkfolio.com/gurus/cliff-asness) 0.2%
- [Joel Greenblatt](https://funkfolio.com/gurus/joel-greenblatt) 0.2%
- [Ray Dalio (founder)](https://funkfolio.com/gurus/bridgewater) 0.1%

Percentages are each holding's share of that investor's reported portfolio (under "Both": GSK / Regeneron Pharmaceuticals). [Who owns GSK](https://funkfolio.com/stock/GSK/superinvestors) · [Who owns REGN](https://funkfolio.com/stock/REGN/superinvestors)

### More on GSK

- [GSK (GSK) stock page](https://funkfolio.com/stock/GSK)
- [GSK market cap](https://funkfolio.com/stock/GSK/market-cap)
- [GSK revenue](https://funkfolio.com/stock/GSK/revenue)
- [GSK P/E ratio](https://funkfolio.com/stock/GSK/pe-ratio)
- [GSK operating margin](https://funkfolio.com/stock/GSK/operating-margin)
- [GSK total debt](https://funkfolio.com/stock/GSK/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Regeneron Pharmaceuticals

- [Regeneron Pharmaceuticals (REGN) stock page](https://funkfolio.com/stock/REGN)
- [Regeneron Pharmaceuticals market cap](https://funkfolio.com/stock/REGN/market-cap)
- [Regeneron Pharmaceuticals revenue](https://funkfolio.com/stock/REGN/revenue)
- [Regeneron Pharmaceuticals P/E ratio](https://funkfolio.com/stock/REGN/pe-ratio)
- [Regeneron Pharmaceuticals operating margin](https://funkfolio.com/stock/REGN/operating-margin)
- [Regeneron Pharmaceuticals total debt](https://funkfolio.com/stock/REGN/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### GSK against its closest peers

- [GSK vs HCA Healthcare](https://funkfolio.com/compare/gsk-vs-hca)
- [GSK vs CVS Health](https://funkfolio.com/compare/cvs-vs-gsk)
- [GSK vs Moderna](https://funkfolio.com/compare/gsk-vs-mrna)

#### Regeneron Pharmaceuticals against its closest peers

- [Regeneron Pharmaceuticals vs Elevance Health](https://funkfolio.com/compare/elv-vs-regn)
- [Regeneron Pharmaceuticals vs HCA Healthcare](https://funkfolio.com/compare/hca-vs-regn)
- [Regeneron Pharmaceuticals vs CVS Health](https://funkfolio.com/compare/cvs-vs-regn)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, GSK or Regeneron Pharmaceuticals?**

By market value, Regeneron Pharmaceuticals is the larger: $99.1B against $98.7B for GSK. By revenue in its latest fiscal year, GSK is the larger: $43.4B against $14.3B for Regeneron Pharmaceuticals.

**Which has the higher P/E ratio?**

Regeneron Pharmaceuticals: 21.1, against 17.6 for GSK. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

**Which has the higher operating margin?**

Regeneron Pharmaceuticals: 24.9%, against 24.3% for GSK. Operating margin is operating income as a share of revenue in the latest fiscal year.

**Which has more debt?**

GSK: $19.2B, against $2B for Regeneron Pharmaceuticals. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

**Which superinvestors own both GSK and Regeneron Pharmaceuticals?**

In their latest 13F filings, Dodge & Cox team and Jeremy Grantham (co-founder) hold both.

### Cite this page

Funkfolio, “GSK vs Regeneron Pharmaceuticals”, data as of 18 November 2026. https://funkfolio.com/compare/gsk-vs-regn

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
